NASDAQ:WINT

Windtree Therapeutics Competitors

$2.14
-0.04 (-1.83 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.03
Now: $2.14
$2.17
50-Day Range
$2.14
MA: $3.43
$5.26
52-Week Range
$2.06
Now: $2.14
$10.06
Volume468,192 shs
Average Volume325,786 shs
Market Capitalization$56.19 million
P/E RatioN/A
Dividend YieldN/A
Beta0.25

Competitors

Windtree Therapeutics (NASDAQ:WINT) Vs. ADMA, LOGC, GMDA, GNFT, TARA, and VYGR

Should you be buying WINT stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Windtree Therapeutics, including ADMA Biologics (ADMA), LogicBio Therapeutics (LOGC), Gamida Cell (GMDA), Genfit (GNFT), Protara Therapeutics (TARA), and Voyager Therapeutics (VYGR).

ADMA Biologics (NASDAQ:ADMA) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider and Institutional Ownership

48.9% of ADMA Biologics shares are owned by institutional investors. Comparatively, 1.6% of Windtree Therapeutics shares are owned by institutional investors. 11.7% of ADMA Biologics shares are owned by company insiders. Comparatively, 14.9% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for ADMA Biologics and Windtree Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADMA Biologics00503.00
Windtree Therapeutics00103.00

ADMA Biologics presently has a consensus target price of $7.80, suggesting a potential upside of 372.73%. Windtree Therapeutics has a consensus target price of $12.25, suggesting a potential upside of 472.43%. Given Windtree Therapeutics' higher probable upside, analysts plainly believe Windtree Therapeutics is more favorable than ADMA Biologics.

Profitability

This table compares ADMA Biologics and Windtree Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADMA Biologics-166.01%-98.83%-37.21%
Windtree TherapeuticsN/A-43.46%-26.55%

Valuation and Earnings

This table compares ADMA Biologics and Windtree Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADMA Biologics$29.35 million6.82$-48,280,000.00($0.92)-1.79
Windtree Therapeutics$200,000.00280.95$-27,480,000.00($2.52)-0.85

Windtree Therapeutics has lower revenue, but higher earnings than ADMA Biologics. ADMA Biologics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ADMA Biologics has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.

Summary

Windtree Therapeutics beats ADMA Biologics on 8 of the 13 factors compared between the two stocks.

Windtree Therapeutics (NASDAQ:WINT) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Insider and Institutional Ownership

1.6% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 33.8% of LogicBio Therapeutics shares are owned by institutional investors. 14.9% of Windtree Therapeutics shares are owned by insiders. Comparatively, 23.4% of LogicBio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Windtree Therapeutics and LogicBio Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Windtree Therapeutics00103.00
LogicBio Therapeutics00303.00

Windtree Therapeutics presently has a consensus price target of $12.25, suggesting a potential upside of 472.43%. LogicBio Therapeutics has a consensus price target of $18.50, suggesting a potential upside of 214.63%. Given Windtree Therapeutics' higher probable upside, equities analysts plainly believe Windtree Therapeutics is more favorable than LogicBio Therapeutics.

Profitability

This table compares Windtree Therapeutics and LogicBio Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Windtree TherapeuticsN/A-43.46%-26.55%
LogicBio TherapeuticsN/A-117.64%-76.85%

Earnings and Valuation

This table compares Windtree Therapeutics and LogicBio Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree Therapeutics$200,000.00280.95$-27,480,000.00($2.52)-0.85
LogicBio TherapeuticsN/AN/A$-40,130,000.00($1.78)-3.30

Windtree Therapeutics has higher revenue and earnings than LogicBio Therapeutics. LogicBio Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Windtree Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

Summary

Windtree Therapeutics beats LogicBio Therapeutics on 6 of the 11 factors compared between the two stocks.

Windtree Therapeutics (NASDAQ:WINT) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Insider and Institutional Ownership

1.6% of Windtree Therapeutics shares are owned by institutional investors. 14.9% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Windtree Therapeutics and Gamida Cell, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Windtree Therapeutics00103.00
Gamida Cell00503.00

Windtree Therapeutics presently has a consensus price target of $12.25, suggesting a potential upside of 472.43%. Gamida Cell has a consensus price target of $20.25, suggesting a potential upside of 164.71%. Given Windtree Therapeutics' higher probable upside, equities analysts plainly believe Windtree Therapeutics is more favorable than Gamida Cell.

Profitability

This table compares Windtree Therapeutics and Gamida Cell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Windtree TherapeuticsN/A-43.46%-26.55%
Gamida CellN/A-112.47%-65.09%

Earnings and Valuation

This table compares Windtree Therapeutics and Gamida Cell's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree Therapeutics$200,000.00280.95$-27,480,000.00($2.52)-0.85
Gamida CellN/AN/A$-34,350,000.00($1.69)-4.53

Windtree Therapeutics has higher revenue and earnings than Gamida Cell. Gamida Cell is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Windtree Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Gamida Cell has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.

Summary

Windtree Therapeutics beats Gamida Cell on 8 of the 11 factors compared between the two stocks.

Windtree Therapeutics (NASDAQ:WINT) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Insider and Institutional Ownership

1.6% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 14.9% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Windtree Therapeutics and Genfit, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Windtree Therapeutics00103.00
Genfit32502.20

Windtree Therapeutics presently has a consensus price target of $12.25, suggesting a potential upside of 472.43%. Genfit has a consensus price target of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher probable upside, analysts plainly believe Genfit is more favorable than Windtree Therapeutics.

Profitability

This table compares Windtree Therapeutics and Genfit's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Windtree TherapeuticsN/A-43.46%-26.55%
GenfitN/AN/AN/A

Earnings and Valuation

This table compares Windtree Therapeutics and Genfit's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree Therapeutics$200,000.00280.95$-27,480,000.00($2.52)-0.85
Genfit$45.88 million3.94$-72,960,000.00($1.97)-2.19

Windtree Therapeutics has higher earnings, but lower revenue than Genfit. Genfit is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Windtree Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Summary

Genfit beats Windtree Therapeutics on 7 of the 13 factors compared between the two stocks.

Windtree Therapeutics (NASDAQ:WINT) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Insider and Institutional Ownership

1.6% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 83.1% of Protara Therapeutics shares are owned by institutional investors. 14.9% of Windtree Therapeutics shares are owned by insiders. Comparatively, 45.7% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Windtree Therapeutics and Protara Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Windtree Therapeutics00103.00
Protara Therapeutics00303.00

Windtree Therapeutics presently has a consensus price target of $12.25, suggesting a potential upside of 472.43%. Protara Therapeutics has a consensus price target of $47.6667, suggesting a potential upside of 201.31%. Given Windtree Therapeutics' higher probable upside, equities analysts plainly believe Windtree Therapeutics is more favorable than Protara Therapeutics.

Profitability

This table compares Windtree Therapeutics and Protara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Windtree TherapeuticsN/A-43.46%-26.55%
Protara TherapeuticsN/A-45.45%-41.09%

Earnings and Valuation

This table compares Windtree Therapeutics and Protara Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree Therapeutics$200,000.00280.95$-27,480,000.00($2.52)-0.85
Protara TherapeuticsN/AN/A$-14,990,000.00N/AN/A

Protara Therapeutics has lower revenue, but higher earnings than Windtree Therapeutics.

Risk & Volatility

Windtree Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500.

Summary

Protara Therapeutics beats Windtree Therapeutics on 5 of the 9 factors compared between the two stocks.

Windtree Therapeutics (NASDAQ:WINT) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Insider and Institutional Ownership

1.6% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of Voyager Therapeutics shares are owned by institutional investors. 14.9% of Windtree Therapeutics shares are owned by insiders. Comparatively, 23.9% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and price targets for Windtree Therapeutics and Voyager Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Windtree Therapeutics00103.00
Voyager Therapeutics08402.33

Windtree Therapeutics presently has a consensus price target of $12.25, suggesting a potential upside of 472.43%. Voyager Therapeutics has a consensus price target of $12.2273, suggesting a potential upside of 168.14%. Given Windtree Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Windtree Therapeutics is more favorable than Voyager Therapeutics.

Profitability

This table compares Windtree Therapeutics and Voyager Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Windtree TherapeuticsN/A-43.46%-26.55%
Voyager Therapeutics-60.61%-66.46%-17.92%

Earnings and Valuation

This table compares Windtree Therapeutics and Voyager Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Windtree Therapeutics$200,000.00280.95$-27,480,000.00($2.52)-0.85
Voyager Therapeutics$104.39 million1.64$-43,600,000.00($1.21)-3.77

Windtree Therapeutics has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Windtree Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.


Windtree Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.65-4.8%$200.10 million$29.35 million-1.92
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$5.88-5.8%$188.31 millionN/A-3.67
Gamida Cell logo
GMDA
Gamida Cell
1.4$7.65-2.2%$185.28 millionN/A-5.35
Genfit logo
GNFT
Genfit
1.3$4.31-2.6%$180.70 million$45.88 million-2.19News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$15.82-1.4%$177.64 millionN/A0.00Increase in Short Interest
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.56-3.5%$171.70 million$104.39 million-2.78
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.99-1.3%$170.58 million$2.45 million-1.87Gap Up
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.27-2.6%$163.04 millionN/A-7.65
INmune Bio logo
INMB
INmune Bio
1.5$10.68-0.8%$160.83 millionN/A-11.01
Axcella Health logo
AXLA
Axcella Health
1.6$4.25-0.2%$160.18 millionN/A-1.98
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.01-3.2%$156.63 millionN/A-2.82
Champions Oncology logo
CSBR
Champions Oncology
1.8$11.06-2.1%$148.09 million$32.12 million-85.08News Coverage
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.91-3.6%$146.40 millionN/A-1.76News Coverage
Gap Up
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.67-5.8%$144.19 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Dyadic International logo
DYAI
Dyadic International
1.3$5.01-1.6%$138.05 million$1.68 million-14.74Increase in Short Interest
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.34-0.0%$137.75 million$20,000.000.00News Coverage
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.45-0.5%$137.63 million$2.33 million0.00
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$12.90-0.6%$131.92 millionN/A0.00Gap Down
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$8.06-3.1%$124.76 million$3 million-2.59Analyst Upgrade
Gap Down
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.21-4.5%$118.28 millionN/A-1.52Analyst Report
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.13-2.6%$111.81 millionN/A-2.98
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.07-2.7%$111.63 million$23.05 million-1.81
PolarityTE logo
PTE
PolarityTE
1.4$0.88-2.3%$106.45 million$5.65 million-0.53Increase in Short Interest
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.14-1.9%$102.81 million$20.92 million-1.23
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.10-0.5%$100.43 million$140,000.000.00
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$9.34-0.5%$68.49 millionN/A0.00Lockup Expiration
BioCardia logo
BCDA
BioCardia
1.5$3.98-3.5%$65.03 million$710,000.00-2.05Analyst Downgrade
Increase in Short Interest
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.12-1.8%$63.77 millionN/A-0.89Gap Up
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.77-1.9%$60.36 million$420,000.00-1.42Increase in Short Interest
Organovo logo
ONVO
Organovo
0.7$8.41-3.7%$59.85 million$2.20 million0.00Gap Down
GENE
Genetic Technologies
0.4$3.87-0.8%$58.16 million$10,000.000.00Gap Down
Brickell Biotech logo
BBI
Brickell Biotech
1.5$0.84-0.0%$56.50 million$7.92 million-0.35News Coverage
Microbot Medical logo
MBOT
Microbot Medical
1.3$7.55-2.3%$53.67 millionN/A0.00Decrease in Short Interest
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.10-1.8%$46.48 million$1.45 million-0.39Increase in Short Interest
Acorda Therapeutics logo
ACOR
Acorda Therapeutics
1.4$4.19-6.2%$39.76 million$192.41 million0.76News Coverage
BiondVax Pharmaceuticals logo
BVXV
BiondVax Pharmaceuticals
0.5$3.09-2.3%$35.08 millionN/A-1.02Decrease in Short Interest
ENTX
Entera Bio
1.2$3.00-10.0%$34.29 million$240,000.00-4.41
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$1.39-2.2%$24.04 million$10,000.000.00Increase in Short Interest
Titan Pharmaceuticals logo
TTNP
Titan Pharmaceuticals
1.2$2.29-0.0%$22.59 million$3.61 million-0.31
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.